Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Blood (2024) 144 (Supplement 1): 568.

https://doi.org/10.1182/blood-2024-207946

Published: 2024

Journal Articles

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Blood (2022) 140 (Supplement 1): 1836–1838.

https://doi.org/10.1182/blood-2022-156309

Published: 2022

Journal Articles

Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Christian T. Dietz, PhD, Alice Charlotte Fabarius, PhD, Michael Lauseker, PhD, Susanne Saussele, Lida Kalmanti, Sébastien Rinaldetti, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martine Jotterand, Alois Gratwohl, Axel R. Zander, Professor, Nicolaus Kröger, Dietrich W. Beelen, MD, Jürgen Novotny, Christoph Nerl, Christof Scheid, MD PhD, Karsten Spiekermann, Jiri Mayer, MD, Herbert G. Sayer, Christiane Falge, Donald Bunjes, MD, Hartmut Döhner, Prof. Dr., Arnold Ganser, Peter Brossart, MD, Rainer Schwerdtfeger, Herrad Baumann, Rolf Kuse, Hans Walter Lindemann, MD, Matthias Bormann, Bernd Hertenstein, MD, Gabriela M. Baerlocher, Carlo Aul, MD, Peter Staib, Matthias Edinger, MD, Michael Schatz, Axel A Fauser, Renate Arnold, MD, Dieter K. Hossfeld, MD, Hans-Jochem Kolb, Susanne Schnittger, PhD, Martin C. Müller, MD, Andreas Reiter, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Joerg Hasford, Michele Baccarani, Ruediger Hehlmann, MD

Blood (2015) 126 (23): 1581.

https://doi.org/10.1182/blood.V126.23.1581.1581

Published: 2015

Journal Articles

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

Blood (2015) 126 (1): 42–49.

https://doi.org/10.1182/blood-2015-01-617993

Published: 2015

Includes: Supplemental data

Journal Articles

Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity

Blood (2013) 122 (21): 1447.

https://doi.org/10.1182/blood.V122.21.1447.1447

Published: 2013

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Utz Krug, Claudia Haferlach, MD, Susanne Schnittger, PhD, Matthias Stelljes, MD, Gerda Silling, MD, Peter Staib, MD, Andreas Grueneisen, MD, Albrecht Reichle, Leopold Balleisen, MD, Hartmut Eimermacher, MD, Aristoteles Giagounidis, MD, Herbert Rasche, MD, Eva Lengfelder, MD, Cristina Sauerland, MSc, Achim Heinecke, PhD, Bernhard Josef Woermann, MD, Wolfgang Hiddemann, MD, PhD

Blood (2012) 120 (21): 1509.

https://doi.org/10.1182/blood.V120.21.1509.1509

Published: 2012

Journal Articles

A novel hierarchical prognostic model of AML solely based on molecular mutations

Vera Grossmann, Susanne Schnittger, Alexander Kohlmann, Christiane Eder, Andreas Roller, Frank Dicker, Christoph Schmid, Clemens-Martin Wendtner, Peter Staib, Hubert Serve, Karl-Anton Kreuzer, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach

Blood (2012) 120 (15): 2963–2972.

https://doi.org/10.1182/blood-2012-03-419622

Published: 2012

Includes: Supplemental data

Journal Articles

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Blood (2011) 118 (21): 2773.

https://doi.org/10.1182/blood.V118.21.2773.2773

Published: 2011

Journal Articles

Prolonged Remission Duration with Interferon Maintenance After Rituximab-Containing Induction in First-Line Advanced Stage Lymphoplasmacytic Lymphoma – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Eva Hoster, Dr., Michael Unterhalt, Dr., Bernd Metzner, Michael Pfreundschuh, MD, Peter Staib, Georg Jacobs, Hans Walter Lindemann, Wolf-Dieter Ludwig, H. Tilman Steinmetz, Lorenz Truemper, Hannes Wandt, Christian Buske, Martin H. Dreyling, PhD, Wolfgang Hiddemann, PhD

Blood (2011) 118 (21): 1639.

https://doi.org/10.1182/blood.V118.21.1639.1639

Published: 2011

Journal Articles

Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Paula Cramer, MD, Stephan Stilgenbauer, MD, Raymonde Busch, Leopold Balleisen, MD, Julia Kilp, MD, Anna-Maria Fink, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Michael Kneba, MD, PhD, Peter Staib, MD, Hartmut Döhner, MD, Silke Schulte, Barbara F. Eichhorst, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2009) 114 (22): 205.

https://doi.org/10.1182/blood.V114.22.205.205

Published: 2009

Journal Articles

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Blood (2009) 114 (22): 485.

https://doi.org/10.1182/blood.V114.22.485.485

Published: 2009

Journal Articles

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.

Blood (2009) 114 (22): 535.

https://doi.org/10.1182/blood.V114.22.535.535

Published: 2009

Journal Articles

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

Francis Giles, Norbert Vey, Daniel DeAngelo, Karen Seiter, Wendy Stock, Robert Stuart, Darinka Boskovic, Arnaud Pigneux, Martin Tallman, Joseph Brandwein, Jonathan Kell, Tadeusz Robak, Peter Staib, Xavier Thomas, Ann Cahill, Maher Albitar, Susan O'Brien

Blood (2009) 114 (19): 4027–4033.

https://doi.org/10.1182/blood-2009-06-229351

Published: 2009

Journal Articles

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG

Blood (2009) 113 (17): 3903–3910.

https://doi.org/10.1182/blood-2008-07-162842

Published: 2009

Journal Articles

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Blood (2008) 112 (11): 325.

https://doi.org/10.1182/blood.V112.11.325.325

Published: 2008

Journal Articles

Older Age Is An Independent Risk Factor in AML

Blood (2008) 112 (11): 555.

https://doi.org/10.1182/blood.V112.11.555.555

Published: 2008

Journal Articles

Related Versus Unrelated Donor Transplantation for High Risk (HiRi) Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).

Joachim Kienast, Hans-Jochem Kolb, Dietrich W. Beelen, Maria Cristina Sauerland, Björna Berning, Albrecht Reichle, Ernst Holler, Renate Arnold, Karin Kolbe, Peter Staib, Rainer Schwerdtfeger, Matthias Stelljes, Christoph Schmid, Claudia Haferlach, Wolfgang E. Berdel, Wolfgang Hiddemann, Thomas Buchner

Blood (2007) 110 (11): 169.

https://doi.org/10.1182/blood.V110.11.169.169

Published: 2007

Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D. Schweighofer, MD, Jasmin Renschler, Raymonde Busch, Michael Kiehl, MD, Leopold Balleisen, MD, Michael Eckart, MD, Anna M. Fink, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Michael Kneba, MD, Peter Staib, MD, Hartmut Doehner, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2007) 110 (11): 3106.

https://doi.org/10.1182/blood.V110.11.3106.3106

Published: 2007

Journal Articles

High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG.

Jan Braess, MD, PhD, Karsten Spiekermann, MD, PhD, Christian Buske, MD, PhD, Peter Staib, MD, PhD, Wolf-Dieter Ludwig, MD, PhD, Andreas Gruneisen, MD, Christa Sauerland, PhD, Michael Unterhalt, MD, PhD, Michael Fiegl, MD, Bernhard Wormann, MD, PhD, Wolfgang Kern, MD, PhD, Achim Heinicke, PhD, Wolfgang Berdel, MD, PhD, Thomas Büchner, MD, PhD, Wolfgang Hiddemann, MD, PhD

Blood (2007) 110 (11): 295.

https://doi.org/10.1182/blood.V110.11.295.295

Published: 2007

NARROW

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups

A novel hierarchical prognostic model of AML solely based on molecular mutations

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Prolonged Remission Duration with Interferon Maintenance After Rituximab-Containing Induction in First-Line Advanced Stage Lymphoplasmacytic Lymphoma – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Older Age Is An Independent Risk Factor in AML

Related Versus Unrelated Donor Transplantation for High Risk (HiRi) Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only